These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 29745928)

  • 1. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Barclay J; Creswell J; León J
    Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for metastatic bladder cancer.
    Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
    Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
    Gwynn ME; DeRemer DL
    Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
    Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
    Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
    Chism DD
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
    Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
    Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade therapy for bladder cancer treatment.
    Kim J
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S98-S105. PubMed ID: 27326412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
    Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
    World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.